ASCO GU 2026 Press Releases

Viewing 1-5 of 5 articles

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Bayer’s XOFIGO® (Radium-223 Dichloride) plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

New Real‑world Data Reinforce Earlier Use of Pluvicto™ Before Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium